Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Inclusion Criteria: * Newly diagnosed acute myeloid leukemia (AML) * No acute promyelocytic leukemia * None of the following cytogenetic abnormalities\*: * t(8;21) * t(16;16) * inv(16) * No history or clinical evidence of primary brain tumors or brain metastasis * Performance status - ECOG 0-2 * No bleeding diathesis or coagulopathy (unless related to AML) * Bilirubin ≤ 2.0 times upper limit of normal (ULN) * ALT ≤ 2.5 times ULN * Creatinine ≤ 2.0 times ULN * No proteinuria * No more than 1 g of protein on 24-hour urine collection * LVEF ≥ 50% * No uncontrolled hypertension * No New York Heart Association class II-IV congestive heart failure * No serious cardiac arrhythmia requiring medication * No peripheral vascular disease ≥ grade II * No stroke within the past 6 months * No arterial thromboembolic event within the past 6 months, including any of the following: * Transient ischemic attack * Cerebrovascular accident * Myocardial infarction * Unstable angina * No other clinically significant cardiovascular disease * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for at least 3-4 months after study participation * No serious or non-healing wound ulcer or bone fracture * No uncontrolled infection * No significant traumatic injury within the past 28 days * No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies * No history or clinical evi…